Pancreatic Cancer Research

ResearcherNara Medical UniversityActive in the last 2 years

Yuichiro Kohara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0268-2450; OpenAlex author ID A5075031142. Sources: OpenAlex.

Their work

Papers
13
Trials
0
Grants
0
Labs led
0
Collaborators
14
Papers, trials and grants by year

2023: 6 papers · 2024: 6 papers · 2025: 1 paper

Papers 13

  1. An axon guidance-related microRNA panel identifies perivascular plexus local recurrence following curative surgery in patients with pancreatic cancer. Co-author DOI 10.1007/s00535-025-02260-w↗
  2. Total neoadjuvant therapy improves survival of patients with borderline resectable pancreatic cancer with arterial involvement. Co-author DOI 10.1002/ags3.12726↗
  3. Prognostic significance of creatine kinase in resected pancreatic cancer. Co-author DOI 10.1002/jhbp.12081↗
  4. Feasibility and efficacy of cell-free and concentrate ascites reinfusion therapy (CART) for advanced pancreatic cancer patients with massive malignant ascites. Co-author DOI 10.1016/j.pan.2024.07.013↗
  5. Clinical impact of carbonic anhydrase 9 expression on neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2024.08.003↗
  6. Clinical significance and therapeutic implication of CD200 in pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.10.007↗
  7. Critical Role of Preoperative Hyperglycemia in Association with GFAT-1 Expression in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-15985-4↗
  8. Importance of triple tumor markers as biomarkers in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12629↗
  9. Essential updates 2021/2022: Surgical outcomes of oligometastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12655↗
  10. Significance of multiple tumor markers measurements in conversion surgery for unresectable locally advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2023.06.001↗
  11. Combination of carbohydrate antigen 19-9 level and tumor size after neoadjuvant chemoradiation therapy may predict early recurrence of resectable pancreatic du… Co-author DOI 10.1016/j.pan.2023.10.014↗
  12. Identification of Nectin Family Interactive Gene Panel and Stratification of Clinical Outcomes in Patients with Pancreatic Cancer. Co-author DOI 10.1097/xcs.0000000000000808↗
  13. Pancreatic ductal adenocarcinoma arising from the pancreatic parenchyma compressed by a huge pancreatic lipoma: a case report. Co-author DOI 10.1186/s40792-023-01720-w↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taichi Terai · 13 shared papers, 2023–2025 · strength 2.60
  2. Masayuki Sho · 13 shared papers, 2023–2025 · strength 2.60
  3. Minako Nagai · 13 shared papers, 2023–2025 · strength 2.60
  4. Satoshi Yasuda · 13 shared papers, 2023–2025 · strength 2.60
  5. Kota Nakamura · 11 shared papers, 2023–2025 · strength 2.18
  6. Satoshi Nishiwada · 5 shared papers, 2023–2025 · strength 0.95
  7. Toshihiro Tanaka · 1 shared paper, 2025 · strength 0.23
  8. Chiharu Uchiyama · 1 shared paper, 2024 · strength 0.21
  9. Takahiro Akahori · 1 shared paper, 2024 · strength 0.21
  10. Shoichi Kinoshita · 1 shared paper, 2024 · strength 0.19
  11. Tadataka Takagi · 1 shared paper, 2023 · strength 0.18
  12. Yuki Imazu · 1 shared paper, 2023 · strength 0.18
  13. Kohei Morita · 1 shared paper, 2023 · strength 0.16
  14. Seiji Nakahara · 1 shared paper, 2023 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.